StockNews.com downgraded shares of Puma Biotechnology (NASDAQ:PBYI - Free Report) from a strong-buy rating to a buy rating in a research report released on Friday morning.
Separately, HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Wednesday, November 20th.
Read Our Latest Stock Report on PBYI
Puma Biotechnology Price Performance
NASDAQ:PBYI traded up $0.05 during mid-day trading on Friday, reaching $3.12. The stock had a trading volume of 546,702 shares, compared to its average volume of 466,594. The stock has a market capitalization of $153.16 million, a P/E ratio of 6.40 and a beta of 1.08. The firm has a 50 day moving average price of $2.89 and a two-hundred day moving average price of $3.09. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. Puma Biotechnology has a one year low of $2.22 and a one year high of $7.73.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the previous year, the business posted $0.12 EPS. As a group, analysts expect that Puma Biotechnology will post 0.31 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in PBYI. SG Americas Securities LLC bought a new stake in Puma Biotechnology in the 3rd quarter worth $34,000. Franklin Resources Inc. bought a new stake in shares of Puma Biotechnology in the third quarter worth about $41,000. Victory Capital Management Inc. bought a new stake in shares of Puma Biotechnology in the second quarter worth about $54,000. Dynamic Technology Lab Private Ltd purchased a new position in Puma Biotechnology during the 3rd quarter valued at about $44,000. Finally, The Manufacturers Life Insurance Company bought a new position in Puma Biotechnology during the 2nd quarter valued at approximately $58,000. 61.29% of the stock is owned by hedge funds and other institutional investors.
About Puma Biotechnology
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Featured Articles
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
